Many patients in trial lost an average of 16 pounds in just nine months.

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Fridays offers a subscription-based weight loss service. Its program includes virtual consultations with a health care provider, compounded GLP-1 medications, lifestyle and nutrition coaching, and ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study’s end. Side effects were ...